4 results
The purpose of this study is to investigate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at up to 16-week intervals to treatment-naive patients with nAMD.
Part 1: Dose-Escalation Stage (not in The Netherlands)Primary objective:* Safety and tolerability of HBM4003Secondary objectives:* Preliminary anti-tumor activities of HBM4003 in advanced solid tumors* Pharmacokinetics (PK) of HBM4003Other…
This study will evaluate the long-term safety and tolerability of IVT faricimab in patients with nAMD who have completed either of the Phase III (GR40306 or GR40844) studies. Additional assessments relating to efficacy, pharmacokinetics,…
primaryTo evaluate the effect of MEDI6570 on non-calcified coronary atherosclerotic plaques compared with placebosecundaryTo evaluate the effect of MEDI6570 on a surrogate biomarker of HF compared with placeboTo evaluate the effect of MEDI6570 on…